Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: A network meta-analysis

Future Oncology

Volumn 11, Issue 3, 2015, Pages 409-420

  Popat, Sanjay ^a   Mellemgaard, Anders ^b   Fahrbach, Kyle ^c   Martin, Alison ^d   Rizzo, Maria ^d   Kaiser, Rolf ^e   Griebsch, Ingolf ^e   Reck, Martin ^f  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d EVIDERA   (United Kingdom)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f GERMAN CENTER FOR LUNG RESEARCH   (Germany)

Author keywords

adenocarcinoma; chemotherapy; nintedanib; NSCLC; second line treatment

Indexed keywords

DOCETAXEL; ERLOTINIB; NINTEDANIB; PEMETREXED; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; INDOLE DERIVATIVE; TAXOID;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LUNG ADENOCARCINOMA; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); GENETICS; LUNG NEOPLASMS; METASTASIS; MORTALITY; MUTATION; PATHOLOGY; RETREATMENT; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; INDOLES; LUNG NEOPLASMS; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; TAXOIDS; TREATMENT OUTCOME;

EID: 84923092623     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.290     Document Type: Article

References (28)

1. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet 382(9893), 709-719 (2013).
2. Ettinger DS, Akerley W, Borghaei H et al. Non-small cell lung cancer. J. Natl Compr. Canc. Netw. 10(10), 1236-1271 (2012).
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-small Cell Lung Cancer, version 2 (2014). www.nccn.org
4. Reck M, Popat S, Reinmuth N et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25(Suppl. 3), iii27-iii39 (2014).
5. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14(3), 253-263 (2009).
6. Scagliotti GV, Parikh P, Von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543-3551 (2008).
7. Hilberg F, Roth GJ, Krssak M et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68(12), 4774-4782 (2008).
8. Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a Phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15(2), 143-155 (2014).
9. Hoaglin DC, Hawkins N, Jansen JP et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14(4), 429-437 (2011).
10. Jansen JP, Fleurence R, Devine B et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14(4), 417-428 (2011).
11. Ciuleanu T, Stelmakh L, Cicenas S et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, Phase 3 study. Lancet Oncol. 13(3), 300-308 (2012).
12. Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized Phase III INTEREST trial. J. Clin. Oncol. 28(5), 744-752 (2010).
13. Nakamura R, Inage Y, Tobita R et al. Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients. J. Thorac. Oncol. 9(9), 1340-1344 (2014).
14. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97(5), 339-346 (2005).
15. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 17(24), 2815-2834 (1998).
16. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521), 897-900 (2005).
17. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23(20), 3105-3124 (2004).
18. Kim ST, Uhm JE, Lee J et al. Randomized Phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75(1), 82-88 (2012).
19. Sun JM, Lee KH, Kim SW et al. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, Phase 3 trial. Cancer 118(24), 6234-6242 (2012).
20. Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol. 26(26), 4244-4252 (2008).
21. Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597 (2004).
22. Garassino MC, Martelli O, Broggini M et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 14(10), 981-988 (2013).
23. Lee DH, Lee JS, Kim SW et al. Three-arm randomised controlled Phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. Eur. J. Cancer 49(15), 3111-3121 (2013).
24. Li N, Ou W, Yang H et al. A randomized Phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma. Cancer 120(9), 1379-1386 (2014).
25. Garon EB, Ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised Phase 3 trial. Lancet 384(9944), 665-673 (2014).
26. Hanna N, Kaiser R, Kim JH et al. Retrospective evaluation of the futility analysis in LUME-Lung 2, a randomised, double-blind, placebo-controlled Phase 3 trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first-line chemotherapy. Eur. J. Cancer 29, 3418 (2013).
27. Kawaguchi T, Ando M, Asami K et al. Randomized Phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J. Clin. Oncol. 32(18), 1902-1908 (2014).
28. Lee CK, Brown C, Gralla RJ et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J. Natl Cancer Inst. 105(9), 595-605 (2013).